Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents

Drugs and Aging

Volumn 29, Issue 12, 2012, Pages 949-956

  Singh, Ravi S J ^a   Kim, Judy E ^a  

^a EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; VASCULOTROPIN INHIBITOR;

CASE STUDY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPTIC NERVE; PERIPHERAL VISION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; VISUAL IMPAIRMENT;

HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; OCULAR HYPERTENSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874630496     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0031-2     Document Type: Review

References (52)

1. Regillo CD, editor. 2007-2008 Basic and clinical science course section 12: retina and vitreous. San Francisco: American Academy of Ophthalmology; 2007.
2. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-72. (Pubitemid 38456293)
3. Guyer DR, Fine SL, Maguire MG, et al. Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol. 1986;104(5):702-5. (Pubitemid 16086738)
4. Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005;123(11):1570-4. (Pubitemid 41626694)
5. Ramulu PY, Do DV, Corcoran KJ, et al. Use of retinal procedures in Medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128(10):1335-40.
6. Day S, Acquah K, Lee PP, et al. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol. 2011;152(6):1014-20.
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-44. (Pubitemid 44511558)
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31. (Pubitemid 44511557)
9. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1982;100(6):912-8.
10. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113(9):1508.e1-25.
11. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113(6):992-1001. (Pubitemid 43795228)
12. Moshfeghi AA, Puliafito CA. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2005;14(5):671-82. (Pubitemid 40790287)
13. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897- 908.
14. Davis J, Olsen TW, Stewart M, et al. How the comparison of age-related macular degeneration treatments trial results will impact clinical care. Am J Ophthalmol. 2011;152(4):509-14.
15. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother. 2012;13(4):585-91.
16. Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(6):930-4.
17. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocular Pharmacol Ther. 2010;26(1):105-10.
18. Bakri SJ, McCannel CA, Edwards AO, et al. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246(7):955-8.
19. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina. 2011;31(6):1028-35.
20. Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95(8):1111-4.
21. Hoang QV, Mendonca LS. Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119(2):321-6.
22. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012;21(4):241-7.
23. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol. 1977;106(1):17-32. (Pubitemid 8160455)
24. Colton T, Ederer F. The distribution of intraocular pressures in the general population. Surv Ophthalmol. 1980;25(3):123-9. (Pubitemid 11200475)
25. Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714-20. (discussion 829-30). (Pubitemid 34620349)
26. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532-8. (Pubitemid 38456289)
27. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805- 16. (Pubitemid 40051904)
28. Bakri SJ, Moshfeghi DM, Rundle A, et al. IOP in eyes treated with monthly ranibizumab: a post hoc analysis of data from the MARINA and ANCHOR Trials. AAO Annual Meeting, 17 Oct 2010, Chicago.
29. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina. 2007;27(8):1044-7. (Pubitemid 350304005)
30. Wilkinson CP, Brinton DA. Retinal detachment principles and practice. 3rd edn. Ophthalmology Monograph. New York: Oxford University Press; 2009.
31. Bushley DM, Parmley VC, Paglen P. Visual field defect associated with laser in situ keratomileusis. Am J Ophthalmol. 2000;129(5):668-71. (Pubitemid 30323738)
32. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma. 2010;19(7):437-41.
33. Kernt M, Welge-Lussen U, Yu A, et al. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe. 2007;104(11):965-71.
34. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2010;30(6):887-92.
35. Liu L, Ammar DA, Ross LA, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011;52(2):1023-34.
36. Freund KB, Laud K, Eandi CM, et al. Silicone oil droplets following intravitreal injection. Retina. 2006;26(6):701-3. (Pubitemid 44620379)
37. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina. 2008;28(7):996-1001.
38. Scott IU, Oden NL, VanVeldhuisen PC, et al. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. Am J Ophthalmol. 2009;148(5):725-32.
39. Perkumas KM, Stamer WD. Protein markers and differentiation in culture for Schlemm's canal endothelial cells. Exp Eye Res. 2012;96(1):82-7.
40. Paylakhi SH, Yazdani S, April C, et al. Non-housekeeping genes expressed in human trabecular meshwork cell cultures. Mol Vis. 2012;18:241-54.
41. Shin JW, Huggenberger R, Detmar M. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood. 2008;112(6):2318-26.
42. Zampell JC, Avraham T, Yoder N, et al. Lymphatic function is regulated by a coordinated expression of lymphangiogenic and anti-lymphangiogenic cytokines. Am J Physiol Cell Physiol. 2012;302(2):C392-404.
43. Singh D. Conjunctival lymphatic system. J Cataract Refract Surg. 2003;29(4):632-3. (Pubitemid 36417997)
44. Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol. 2012;23(2):105-10.
45. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98.
46. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566-83. (Pubitemid 46452533)
47. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58.e1.
48. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663-71.
49. Theoulakis PE, Lepidas J, Petropoulos IK, et al. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd. 2010;227(4):280-4.
50. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128(12):1523-7.
51. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000;11(2):94-100. (Pubitemid 30164028)
52. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42(6):807-11.